Influence of dapagliflozin on left ventricular diastolic function in patients with chronic heart failure complicated by type 2 diabetes mellitus
Yang Guangquan
Zhan Qinglei
Wu Fuxuan.
Abstract：Objective To investigate the influence of inhibitors of sodium-glucose cotransporter 2 (SGLT2, dapagliflozin) on left ventricular diastolic function in patients with chronic heart failure (CHF) complicated by type 2 diabetes mellitus (T2DM). Methods The patients with CHF complicated by T2DM (n=52) were chosen from Department of Cardiovascular Medicine of Municipal Hospital of Heze City from Nov. 2016 to Feb. 2017. All patients did not take SGLT2 inhibitors ever before and they had taken other antidiabetic drugs for at least 1y, then they were treated with dapagliflozin for 6 months. The patients were given examinations of laboratory and chocardiography before the study and after treatment for 6 months. The primary endpoint was the ratio of left ventricular peak early diastolic mitral flow velocity to diastolic mitral annular velocity (E/e’) at the beginning of treatment and 6 months after treatment, and the secondary endpoints included left ventricular mass index (LVMI) and left atrial volume index (LAVI) before and after treatment. Results After treatment for 6 months, E/e’ decreased from 8.9 to 7.8 (P=0.018). LAVI decreased from 30.8 ml/m2 to 24.8 ml/m2 (P=0.015), and LVMI decreased from 74.2 g/m2 to 66.1 g/m2 (P=0.012). Conclusion SGLT2 inhibitor-dapagliflozin can improve left ventricular diastolic function in patients with CHF complicated by T2DM, which can be a new direction for clinical practice.
Keywords：Inhibitor of sodium-glucose cotransporterChronic heart failureType 2 diabetes mellitusLeft ventricular diastolic function
Publication Date：2019-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1118-1120,1124 )